TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW 60
1.4 CURRENCY AND PRICING 62
1.5 LIMITATIONS 62
1.6 MARKETS COVERED 62
2 MARKET SEGMENTATION 68
2.1 MARKETS COVERED 68
2.2 GEOGRAPHICAL SCOPE 69
2.3 YEARS CONSIDERED FOR THE STUDY 70
2.4 DBMR TRIPOD DATA VALIDATION MODEL 71
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
2.6 MULTIVARIATE MODELLING 75
2.7 PRODUCTS LIFELINE CURVE 75
2.8 DBMR MARKET POSITION GRID 76
2.9 SECONDARY SOURCES 78
2.10 ASSUMPTIONS 78
3 EXECUTIVE SUMMARY 79
4 PREMIUM INSIGHT 83
4.1 PESTEL ANALYSIS 85
4.2 PORTER'S FIVE FORCES MODEL 86
4.3 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET ANALYSIS 87
4.4 PATENT ANALYSIS 88
5 PIPELINE ANALYSIS 90
6 EPIDEMIOLOGY 91
7 INDUSTRY INSIGHTS 92
7.1 DEMOGRAPHIC TRENDS 92
7.2 KEY PRICING STRATEGIES 94
7.3 KEY PATIENT ENROLLMENT STRATEGIES 95
8 REGULATORY SCENARIO FOR MEDICAL FOOD 97
9 MARKET OVERVIEW 100
9.1 DRIVERS 102
9.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM (IEM) 102
9.1.2 RISING PREFERENCE FOR DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY (ERT) 103
9.1.3 INCREASE IN THE NUMBER OF NEW-BORN SCREENING PROCEDURES 104
9.1.4 INCREASING SPENDING ON MEDICAL FOOD PRODUCTS 105
9.2 RESTRAINTS 106
9.2.1 HIGH COST OF MEDICAL FOODS 106
9.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS 107
9.3 OPPORTUNITIES 108
9.3.1 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT INBORN ERRORS OF METABOLISM 108
9.3.2 INCREASING COLLABORATIONS AND PARTNERSHIPS IN THE MARKET 110
9.3.3 EXPANSION OF MEDICAL FOODS IN EMERGING MARKETS 110
9.4 CHALLENGES 111
9.4.1 POOR ACCESSIBILITY OF MEDICAL FOODS 111
9.4.2 ALTERNATIVE TREATMENT APPROACHES FOR INBORN ERRORS OF METABOLISM 112
10 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS 113
10.1 OVERVIEW 114
10.2 AMINO ACID 117
10.2.1 AMINO ACID MIXTURES 118
10.2.1.1 PHENYLADE 119
10.2.1.1.1 DRINK MIX 119
10.2.1.1.2 GMP MIX-IN 119
10.2.1.1.3 GMP READY 119
10.2.1.1.4 OTHERS 119
10.2.1.2 PERIFLEX 119
10.2.1.3 LOPHLEX 120
10.2.1.4 PHLEXY 120
10.2.1.5 COOLER 120
10.2.1.6 ANAMIX 120
10.2.1.7 LYSINE-FREE, LOW TRYPTOPHAN 120
10.2.1.8 GLUTARADE ESSENTIAL GA-1 120
10.2.1.9 GLUTARADE GA-1 AMINO ACID BLEND 120
10.2.1.10 GLYTACTIN WITH GMP 120
10.2.1.11 ESSENTIAL AMINO ACID MIX 120
10.2.1.12 LIQUIGEN 120
10.2.1.13 MSUD GEL 121
10.2.1.14 OTHERS 121
10.2.2 SINGLE AMINO ACID 121
10.2.2.1 L-ARGININE 121
10.2.2.2 L-ISOLEUCINE 121
10.2.2.3 L-TYROSINE 122
10.2.2.4 L-LEUCINE 122
10.2.2.5 GLYCINE 122
10.2.2.6 L-ASPARTIC ACID 122
10.2.2.7 L-CITRULLINE 122
10.2.2.8 OTHERS 122
10.3 LOW PROTEIN FOOD 122
10.3.1 LOW-PROTEIN BAKING MIXES AND FLOUR SUBSTITUTES, SUCH AS RICE FLOUR OR POTATO FLOUR 124
10.3.2 LOW-PROTEIN ENERGY BARS AND SNACKS 124
10.3.3 LOW-PROTEIN CEREALS AND BREAKFAST FOOD 124
10.3.4 LOW-PROTEIN MILK SUBSTITUTES, SUCH AS RICE MILK OR ALMOND MILK 124
10.3.5 LOW-PROTEIN BREAD, PASTA, AND OTHER GRAIN-BASED PRODUCTS 124
10.3.6 OTHERS 124
10.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON 124
10.4.1 BY FLAVOUR 125
10.4.1.1 VANILLA 125
10.4.1.2 BERRY 125
10.4.1.3 ORANGE 126
10.4.1.4 PLAIN 126
10.4.1.5 OTHERS 126
10.4.2 BY USAGE 126
10.4.2.1 READY TO DRINK 126
10.4.2.2 NEED DILUTION/PREPARATION 126
10.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON 127
10.5.1 NO CALCIUM OR VITAMIN D 128
10.5.2 LOW CALCIUM, NO VITAMIN D 128
10.5.3 OTHERS 128
10.6 OTHERS 128
11 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES 130
11.1 OVERVIEW 131
11.2 PHENYLKETONURIA (PKU) 134
11.2.1 PHENYLADE 135
11.2.2 PERIFLEX 135
11.2.3 LOPHLEX 135
11.2.4 OTHERS 135
11.3 TYROSINEMIA TYPES I AND II 135
11.4 MAPLE SYRUP URINE DISEASE (MSUD) 136
11.4.1 ANAMIX 137
11.4.2 COOLER 137
11.4.3 MSUD GEL 137
11.4.4 AMINO ACID BLEND 137
11.4.5 MAXMUM 137
11.4.6 OTHERS 137
11.5 HOMOCYSTINURIA 138
11.6 GLUTARIC ACIDEMIA TYPE I 138
11.7 UREA CYCLE DISORDERS 139
11.7.1 ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) 140
11.7.2 CARBAMYL PHOSPHATE SYNTHETASE DEFICIENCY (CPS) 140
11.7.3 CITRULLINAEMIA 140
11.7.4 N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY (NAGS) 140
11.7.5 ARGINASE DEFICIENCY (AG) 141
11.7.6 ARGININOSUCCINIC ACIDURIA (ASA) 141
11.7.7 OTHERS 141
11.8 METHYLMALONIC ACIDEMIA 141
11.9 ISOVALERIC ACIDEMIA 142
11.10 ORGANIC ACIDURIAS 143
11.11 RENAL DISEASE 143
11.12 PROPIONIC ACIDEMIA 144
11.13 DISORDERS OF LEUCINE METABOLISM 145
11.14 OTHERS 146
12 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP 147
12.1 OVERVIEW 148
12.2 INFANTS 151
12.3 WEANING 151
12.4 ADOLESCENT 152
12.5 ADULTS 153
13 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS 154
13.1 OVERVIEW 155
13.2 POWDER 158
13.3 LIQUID 158
13.4 TABLETS 159
13.5 GELS 160
13.6 OTHERS 161
14 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING 162
14.1 OVERVIEW 163
14.2 CAN 166
14.3 PACKETS 166
14.4 BOTTLE 167
14.5 JAR 168
14.6 OTHERS 168
15 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL 170
15.1 OVERVIEW 171
15.2 HOSPITAL PHARMACY 174
15.3 RETAIL PHARMACY 174
15.4 DRUG STORES 175
15.5 ONLINE PHARMACY 176
15.6 OTHERS 176
16 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION 178
16.1 OVERVIEW 179
16.2 NORTH AMERICA 184
16.2.1 U.S. 195
16.2.2 CANADA 202
16.2.3 MEXICO 209
16.3 EUROPE 216
16.3.1 GERMANY 230
16.3.2 FRANCE 239
16.3.3 U.K. 248
16.3.4 ITALY 257
16.3.5 SPAIN 266
16.3.6 SWITZERLAND 276
16.3.7 NETHERLANDS 285
16.3.8 BELGIUM 294
16.3.9 DENMARK 303
16.3.10 RUSSIA 312
16.3.11 SWEDEN 320
16.3.12 TURKEY 328
16.3.13 POLAND 336
16.3.14 FINLAND 344
16.3.15 NORWAY 351
16.3.16 REST OF EUROPE 359
16.4 ASIA-PACIFIC 360
16.4.1 CHINA 375
16.4.2 JAPAN 385
16.4.3 INDIA 394
16.4.4 AUSTRALIA 404
16.4.5 SOUTH KOREA 414
16.4.6 THAILAND 423
16.4.7 SINGAPORE 433
16.4.8 INDONESIA 442
16.4.9 MALAYSIA 451
16.4.10 NEW ZEALAND 460
16.4.11 VIETNAM 468
16.4.12 PHILIPPINES 476
16.4.13 TAIWAN 486
16.4.14 REST OF ASIA-PACIFIC 495
16.5 SOUTH AMERICA 496
16.5.1 BRAZIL 508
16.5.2 ARGENTINA 515
16.5.3 REST OF SOUTH AMERICA 523
16.6 MIDDLE EAST AND AFRICA 524
16.6.1 SOUTH AFRICA 535
16.6.2 SAUDI ARABIA 542
16.6.3 BAHRAIN 549
16.6.4 UNITED ARAB EMIRATES 557
16.6.5 KUWAIT 564
16.6.6 QATAR 572
16.6.7 EGYPT 579
16.6.8 OMAN 586
16.6.9 REST OF MIDDLE EAST AND AFRICA 593
17 GLOBAL MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE 594
17.1 COMPANY SHARE ANALYSIS: GLOBAL 594
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 595
17.3 COMPANY SHARE ANALYSIS: EUROPE 596
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 597
18 SWOT ANALYSIS 598
19 COMPANY PROFILE 599
19.1 ABBOTT 599
19.1.1 COMPANY SNAPSHOT 599
19.1.2 REVENUE ANALYSIS 599
19.1.3 COMPANY SHARE ANALYSIS 600
19.1.4 PRODUCT PORTFOLIO 600
19.1.5 RECENT DEVELOPMENT 601
19.2 NESTL HEALTH SCIENCE (A SUBSIDIARY OF NESTL) 602
19.2.1 COMPANY SNAPSHOT 602
19.2.2 COMPANY SHARE ANALYSIS 602
19.2.3 PRODUCT PORTFOLIO 603
19.2.4 RECENT DEVELOPMENT 603
19.3 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.) 604
19.3.1 COMPANY SNAPSHOT 604
19.3.2 COMPANY SHARE ANALYSIS 604
19.3.3 PRODUCT PORTFOLIO 605
19.3.4 RECENT DEVELOPMENTS 605
19.4 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.) 606
19.4.1 COMPANY SNAPSHOT 606
19.4.2 COMPANY SHARE ANALYSIS 606
19.4.3 PRODUCT PORTFOLIO 607
19.4.4 RECENT DEVELOPMENT 607
19.5 NUTRICIA (A SUBSIDIARY OF DANONE) 608
19.5.1 COMPANY SNAPSHOT 608
19.5.2 COMPANY SHARE ANALYSIS 608
19.5.3 PRODUCT PORTFOLIO 609
19.5.4 RECENT DEVELOPMENT 610
19.6 APR 611
19.6.1 COMPANY SNAPSHOT 611
19.6.2 PRODUCT PORTFOLIO 611
19.6.3 RECENT DEVELOPMENT 611
19.7 B.BRAUN SE 612
19.7.1 COMPANY SNAPSHOT 612
19.7.2 PRODUCT PORTFOLIO 612
19.7.3 RECENT DEVELOPMENT 612

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.